A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Rituximab will be administered intravenously through Cycle 1-8 at a standard dose of 375 mg/m\^2 (milligram per square meter).

Rituximab will be administered subcutaneously through Cycle 2-8 at a dose of 1400 milligram (mg).

Rituximab will be administered intravenously in Cycle 1 at a standard dose of 375 mg/m\^2.

Cyclophosphamide will be administered IV at a dose of 750 mg/m\^2

Doxorubicin will be administered IV at a dose of 50 mg/m\^2

Vincristine will be administered IV at a dose of 1.4 mg/m\^2

Prednisone will be administered orally at a dose of 100 mg/day

All participants are required to receive 1000 mg oral paracetamol as premedication prior to starting each infusion of rituximab

All participants are required to receive 50-100 mg oral diphenhydramine hydrochloride or alternative antihistamine as premedication prior to starting each infusion of rituximab